Sanofi Pasteur and MedImmune Collaborate on Monoclonal Antibody to Prevent Illnesses Associated with RSV
(Thomson Reuters ONE) -
Sanofi Pasteur and MedImmune Collaborate on Monoclonal Antibody to Prevent
Illnesses Associated with RSV
- Respiratory Syncytial Virus is the most common cause of lung inflammation and
pneumonia in infants -
Paris, France - March 3, 2017 - Sanofi and its vaccines global business unit
Sanofi Pasteur announced today an agreement with MedImmune, the global biologics
research and development arm of AstraZeneca, to develop and commercialize a
monoclonal antibody--called MEDI8897--for the prevention of Respiratory
Syncytial Virus (RSV) associated illness in newborns and infants. According to
the Centers for Disease Control and Prevention, RSV is the most common cause of
lower respiratory tract infections in children younger than 1 year of age in the
United States and worldwide.
MEDI8897 is a highly potent monoclonal antibody (mAb) that neutralizes RSV by
binding the RSV fusion (F) protein expressed on virions and infected cells; it
has been engineered to have a long half-life so that only one dose would be
needed for the entire RSV season. It is being developed for the passive
immunization of the infant population. MEDI8897 is currently being investigated
in a Phase IIb study in preterm infants with plans for a Phase III trial in
healthy full-term infants. MEDI8897 received fast-track designation from the
U.S. FDA in 2015.
"RSV is considered to be the most important missing indication in the
vaccination schedule of newborns," said David Loew, Sanofi Executive Vice
President and head of Sanofi Pasteur. "As a global leader in the pediatric
vaccine industry, this deal with MedImmune therefore makes perfect sense for
Sanofi Pasteur. RSV causes major, seasonal worldwide outbreaks and the severity
is predominant among young infants," he continued. "We look forward to working
with MedImmune to offer a solution to this common lower-respiratory disease when
infants are most vulnerable."
Under the terms of the agreement, Sanofi Pasteur will make an upfront payment of
?120 million and pay up to ?495 million upon achievement of certain development
and sales-related milestones. The two companies will share all costs and profits
equally. MedImmune will continue to lead all development activity up to the
first approval, and AstraZeneca will retain MEDI8897 manufacturing activities.
Sanofi-Pasteur will lead the commercialization activities for MEDI8897.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi is organized into five
global business units: Diabetes and Cardiovascular, General Medicines and
Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi
is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion
doses of vaccine each year, making it possible to immunize more than 500 million
people across the globe. A world leader in the vaccine industry, Sanofi Pasteur
produces a portfolio of high quality vaccines that matches its areas of
expertise and meets public-health demand. The company's heritage, to create
vaccines that protect life, dates back more than a century. Sanofi Pasteur is
the largest company entirely dedicated to vaccines. Every day, the company
invests more than EUR 1 million in research and development. For more
information, please visit: www.sanofipasteur.com
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include
projections and estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to future financial
results, events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many
of which are difficult to predict and generally beyond the control of Sanofi,
that could cause actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other things, the
uncertainties inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product candidates as well
as their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence of
guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, Sanofi's ability to benefit from external growth opportunities
and/or obtain regulatory clearances, risks associated with intellectual property
and any related pending or future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest rates, volatile
economic conditions, the impact of cost containment initiatives and subsequent
changes thereto, the average number of shares outstanding as well as those
discussed or identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for
the year ended December 31, 2015. Other than as required by applicable law,
Sanofi does not undertake any obligation to update or revise any forward-looking
information or statements.
--------------------------------------------------------------------------------
Contacts:
Media Relations Investor Relations
Laurence Bollack George Grofik
Tel.: +33 (0)1 53 77 46 46 Tel.: +33 (0)1 53 77 45 45
mr(at)sanofi.com ir(at)sanofi.com
Press Release (PDF):
http://hugin.info/152918/R/2084549/785858.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 03.03.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 527934
Anzahl Zeichen: 8005
contact information:
Town:
PARIS
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 211 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sanofi Pasteur and MedImmune Collaborate on Monoclonal Antibody to Prevent Illnesses Associated with RSV"
steht unter der journalistisch-redaktionellen Verantwortung von
Sanofi (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
